Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study

1. M.E. LACOUTURE. Importance of dermatological care for patients with cancer, The Asco Post, 2012, http://www.ascopost.com/issues/september-15-2012/importance-of-dermatologic-care-for-patients-with-cancer/ [accessed December 2017].Search in Google Scholar

2. CHMIELOWSKI B., TERRITO M. Cutaneous Complications in: Manual of clinical oncology, Wolters Kluwer, Philadelphia, 2017: 29.Search in Google Scholar

3. GULATTE M. Symptom Management in: Clinical guide to antineoplastic therapy – a chemotherapy handbook, Oncology Nursing Society, Pittsburgh, Pennsylvania, 2014:13.Search in Google Scholar

4. BOERS-DOETS C.B. How to measure the impact of dermatologic and mucosal adverse events on symptom burden and quality of life, The Asco Post, 2013, http://www.ascopost.com/issues/december-15-2013/how-to-measure-the-impact-of-dermatologicand-mucosal-adverse-events-on-symptom-burden-and-quality-of-life/?utm_source=TrendMD&utm_medium=cpc&utm_campaign=The_ASCO_Post_TrendMD_0 [accessed December 2017].Search in Google Scholar

5. NATIONAL CANCER INSTITUTE – DIVISION OF CANCER TREATMENT AND DIAGNOSIS, Cancer therapy evaluation program, https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm [accessed December 2017].Search in Google Scholar

6. FINLAY AY, KHAN GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clinical and Experimental Dermatology. 1994; 19(3):201-6.10.1111/j.1365-2230.1994.tb01167.xSearch in Google Scholar

7. DEPARTMENT OF DERMATOLOGY, QUALITY OF LIFE QUESTIONNAIRES, CARDIFF UNIVERSITY, http://sites.cardiffac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/. [accessed December 2017].Search in Google Scholar

8. HOFHEINZ RD, DEPLANQUE G, KOMATSU Y, KOBAYASHI Y, OCVIRK J, RACCA P et al. Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhbitors in patients with solid tumors, The Oncologist. 2016; 21:1-9.10.1634/theoncologist.2016-0051Search in Google Scholar

9. LACOUTURE ME. Skin conditions can have severe impact in cancer patients, Oncology, 2011, http://www.practiceupdate.com/content/skin-conditions-can-have-severe-impact-in-cancer-patients/13155/62?trendmd-shared=1 [accessed December 2017].Search in Google Scholar

10. PEREZ-SOLER R, CHACHOUA A, HAMMOND LA, ROWINSKY EK, HUBERMAN M, KARP D, et al. Determinants of tumor response and survival with erlotinib in patients with non small cell lung cancer, J Clin Oncol. 2004; 22(16):3238-47.10.1200/JCO.2004.11.057Search in Google Scholar

11. VAN CUTSEM E, TEIPAR S, VANBECKEVOORT D, PEETERS M, HUMBLET Y, GELDERBLOM H et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study, J Clin Oncol. 2012; 30(23):2861-8.10.1200/JCO.2011.40.9243Search in Google Scholar

12. PINTO C, DI FABIO F, ROSATI G, LOLLI IR, RUGGERI EM, CIUFFREDA L, et al. Observational study on quality of life, safety and effectiveness of first line cetuximab plus chemotherapy in KRAS wild type metastatic colorectal cancer patients: the Observ Er Study. Cancer Med. 2016; 5(11):3272-81.10.1002/cam4.888511998327748041Search in Google Scholar